WO2018112739A1 - 一种假小链状双歧杆菌及其培养方法和应用 - Google Patents

一种假小链状双歧杆菌及其培养方法和应用 Download PDF

Info

Publication number
WO2018112739A1
WO2018112739A1 PCT/CN2016/111026 CN2016111026W WO2018112739A1 WO 2018112739 A1 WO2018112739 A1 WO 2018112739A1 CN 2016111026 W CN2016111026 W CN 2016111026W WO 2018112739 A1 WO2018112739 A1 WO 2018112739A1
Authority
WO
WIPO (PCT)
Prior art keywords
bifidobacterium breve
bifidobacterium
pharmaceutical composition
acid
preparation
Prior art date
Application number
PCT/CN2016/111026
Other languages
English (en)
French (fr)
Inventor
邹远强
薛文斌
肖亮
李晓平
余靖宏
刘传
Original Assignee
深圳华大基因研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳华大基因研究院 filed Critical 深圳华大基因研究院
Priority to PCT/CN2016/111026 priority Critical patent/WO2018112739A1/zh
Priority to CN201680091077.1A priority patent/CN110023484B/zh
Publication of WO2018112739A1 publication Critical patent/WO2018112739A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/02—Acetobacter

Definitions

  • the invention relates to the technical field of microorganisms, in particular to a Bifidobacterium pseudocatenulatum and a culture method and application thereof.
  • the human intestine is composed of a large number of microorganisms. These microorganisms are numerous and large in number, forming a complex ecosystem in the human intestine, and the composition of the microorganisms is closely related to human health. Numerous studies have shown that intestinal microbes are closely related to many diseases, such as diabetes, obesity, hyperlipidemia and other metabolic diseases and inflammatory diseases such as colitis and rheumatoid arthritis. Most of the microorganisms in the intestines of healthy human beings are beneficial bacteria and are indispensable for human health. Among them, bifidobacteria are an important bacteria in human intestinal tract. Bifidobacteria are established in the intestines of infants from birth.
  • Bifidobacteria As the age increases, the content of bifidobacteria gradually decreases. Bifidobacteria have important effects such as anti-inflammatory, anti-tumor, anti-aging and inhibition of harmful bacteria. Bifidobacteria can also stimulate intestinal peristalsis by producing short-chain fatty acids (SCFA) and organic acids to prevent constipation and other diseases.
  • SCFA short-chain fatty acids
  • Ulcerative colitis is a type of Inflammatory bowel disease (IBD), a chronic intestinal inflammatory disease with unknown pathogenesis.
  • IBD Inflammatory bowel disease
  • Clinical pathological studies suggest that the pathogenesis of UC is mainly related to the individual susceptibility genes and the intestinal mucosal immune response induced by intestinal micro-organisms. The symptoms are mainly persistent abdominal pain, diarrhea and mucous bloody stools, and the disease is repeated, and the onset can be seen at any age.
  • the main clinical drugs for UC are salicylic acid, glucocorticoids, and immunological preparations.
  • Salicylic acid drugs can better inhibit prostaglandin synthesis and scavenge oxygen free radicals to achieve the purpose of relieving inflammatory reaction.
  • the common salicylate western medicine used in the treatment of UC is mainly sulfasalazine (SASP), mainly for light Patients with moderate, moderate, and chronic UC; glucocorticoids are patients with severe or fulminant UC
  • SASP sulfasalazine
  • the preferred drug such as betamethasone
  • immunosuppressants such as cyclosporine can inhibit UC by inhibiting the production of IL-2 in T cells and affecting the progression of the immune response.
  • the three types of drugs for UC can alleviate UC to some extent, but there are certain side effects.
  • the side effects of salicylic acid are gastrointestinal reactions, headache, reticulocyte increase, sperm reduction and allergic reaction. Caused by rash, liver toxicity, leukopenia, anemia, etc.
  • Glucocorticoids cause side effects such as metabolic disorders and water retention, which can only be used as an emergency medication and cannot be taken for a long time.
  • Immunosuppressive therapy is highly dependent on drugs, has a long treatment period, and is prone to cause nephrotoxicity and secondary infection. It can only be used as a means of adjuvant therapy.
  • the present invention provides a novel species of Bifidobacterium breve, which has the effect of preventing and/or treating ulcerative colitis.
  • the present invention further provides a method for cultivating the new gut bacterial species, a product thereof, and an application thereof.
  • the present invention provides a Bifidobacterium pseudocatenulatum TM12-14 deposited with the Guangdong Provincial Collection of Microorganisms and Cultures under the accession number GDMCC 60089.
  • the present invention provides a method for culturing the Bifidobacterium breve Bifidobacterium TM12-14 of the first aspect, which is inoculated into PYG medium. Anaerobic culture is carried out.
  • a microecological preparation comprising the Bifidobacterium breve Bifidobacterium TM12-14 of the first aspect and/or a metabolite thereof.
  • microecological preparations As is generally understood in the art, all formulations which promote the growth and reproduction of normal microbial populations and inhibit the growth and reproduction of pathogenic bacteria are referred to as "microecological preparations".
  • microecological preparation refers to a preparation made of Bifidobacterium fuliginea TM12-14 and/or its metabolite, which has a regulation of the intestinal tract. Efficacy, rapid construction of intestinal micro-ecological balance.
  • a typical microecological preparation may be a probiotic preparation for the prevention/treatment of ulcerative enteritis.
  • Bifidobacterium fuliginea TM12-14 has the effect of treating ulcerative enteritis, and can further maintain the activity of the strain by further changing the type of probiotic preparation, using different packaging and processing methods, such as embedding technology.
  • the corresponding therapeutic effect can be achieved by reaching the corresponding therapeutic effect, or by additionally adding prebiotics (bacteria powder, oligosaccharide, etc.) in combination with Bifidobacterium breve TM12-14 to treat ulcerative enteritis.
  • prebiotics bacteria powder, oligosaccharide, etc.
  • the probiotics Bifidobacterium breve TM12-14 of the present invention can alleviate ulcerative enteritis, and may also exert its therapeutic effects in other inflammation-related diseases (common enteritis, gastritis, etc.).
  • the present invention provides a food composition, a nutraceutical or an auxiliary additive comprising the Bifidobacterium breve Bismuth TM12-14 of the first aspect and/or a metabolite thereof.
  • the food composition of the present invention may contain various food materials, food additives, and the like, such as milk, white sugar, vitamins, and the like, in addition to Bifidobacterium fuliginea TM12-14 and/or its metabolites.
  • Excipient additives in the present invention such as various edible additives.
  • the present invention provides a pharmaceutical composition comprising the Bifidobacterium fuliginea TM12-14 of the first aspect and/or a metabolite thereof.
  • the pharmaceutical composition of the present invention may contain various pharmaceutically acceptable carriers and/or adjuvants in addition to Bifidobacterium fuligis TM12-14 and/or its metabolites, including but not limited to: lactose , yeast powder, peptone, purified water, starch and vitamins, etc., may also contain various excipients, and can be formulated into tablets or capsules. Further, the pharmaceutical composition of the present invention may further contain a substance which contributes to the maintenance of the activity of Bifidobacterium breve TM12-14, such as a protective agent, and a typical, but non-limiting protective agent is vitamin C.
  • the content of Bifidobacterium smegmatis TM12-14 may be, for example, but not limited to, typically 1 x 10 -1 to 1 x, based on the total volume or total weight of the pharmaceutical composition. 10 20 cfu/mL or cfu/g of Bifidobacterium breve TM12-14, preferably containing 1 ⁇ 10 4 to 1 ⁇ 10 15 cfu/mL or cfu/g of Bifidobacterium breve TM12 -14.
  • the present invention provides the use of the Bifidobacterium fuliginea TM12-14 of the first aspect for the preparation of a medicament for preventing and/or treating ulcerative colitis.
  • the present invention provides the use of the Bifidobacterium breve TM12-14 of the first aspect in the preparation of a microecological preparation.
  • the invention provides the use of the Bifidobacterium breve TM12-14 of the first aspect in the production of an organic acid.
  • the organic acid in the present invention especially refers to a short-chain fatty acid (SCFA) such as formic acid, acetic acid, butyric acid, etc., and the organic acid may further include 3-methylbutyric acid, valeric acid, quinic acid, lactic acid, oxalic acid, and C.
  • SCFA short-chain fatty acid
  • the organic acid may further include 3-methylbutyric acid, valeric acid, quinic acid, lactic acid, oxalic acid, and C.
  • the present invention provides the use of the Bifidobacterium breve TM12-14 of the first aspect for producing a short-chain fatty acid.
  • the present invention provides a method for preventing and/or treating ulcerative colitis comprising administering to a subject a Ps. Pharmaceutical composition.
  • the invention provides a method of lowering blood lipids, controlling a decrease in body weight of a mammal, and/or reducing a disease activity index (DAI) of a mammal, comprising administering to the subject a first aspect Pseudomonas aeruginosa TM12-14 or a pharmaceutical composition of the fifth aspect.
  • DAI disease activity index
  • the subject may be a human or other mammal.
  • the Bifidobacterium breve Bismuth TM12-14 of the present invention has obvious remission effect on ulcerative enteritis, which can significantly improve the apparent state of mice with ulcerative colitis and reduce the disease activity of mice. Index, and reduce the inflammatory response in mice, while having the ability to lower cholesterol. Therefore, the Bifidobacterium breve TM12-14 can be made into a microecological preparation, a food composition, a pharmaceutical composition And other products for the prevention and / or treatment of ulcerative enteritis.
  • Figure 1 shows a picture of colonies of Bifidobacterium breve TM12-14 cultured for 48 hours.
  • the colonies are white, convex, round, with neat edges and colonies about 1-2 mm in diameter.
  • Figure 2 shows a Gram-stained picture of microscopy of Bifidobacterium breve TM12-14 under microscope (1000 times). The cells showed a divergent rod shape, positive for Gram stain, and no spores and flagella.
  • Figure 3 shows the cholesterol standard curve, using phthalaldehyde colorimetric method (OPA method) for cholesterol detection by using different concentrations (20ug/mL, 40ug/mL, 60ug/mL, 80ug/mL) of cholesterol and OPA The reaction was developed to obtain a standard curve.
  • OPA method phthalaldehyde colorimetric method
  • Figure 4 shows changes in body weight of control, model group, VSL # 3 and TM12-14 treatment groups.
  • Figure 5 shows the changes in the DAI index of the control, model group, VSL # 3 and TM12-14 treatment groups.
  • Example 1 Isolation and Identification of Bifidobacterium breve TM12-14
  • the isolated sample was obtained from a 14-year-old healthy male feces, and the feces were collected into sterile sample tubes and brought back to the laboratory for sorting within 1 h.
  • the solid medium was added to 1.5% agar and poured in an anaerobic operation box.
  • the obtained pure culture strain was cultured to a concentration of about 10 9 cfu/ml, and 400 ul of bacterial liquid was added to add 40% glycerol to 400 ul to achieve a glycerin concentration of 20%, and then subjected to -80 ° C cryopreservation.
  • the obtained isolated strain was cultured in a liquid PYG medium for 24 hours, and 1 ml of the bacterial liquid was centrifuged at 10,000 r/min for 5 minutes, and the bacterial cells were collected to extract genomic DNA.
  • 16S rDNA universal primers 8F-AGAGTTTGATCATGGCTCAG (SEQ ID NO: 1) and 1492R-TAGGGTTACCTTGTTACGACTT (SEQ ID NO: 2)) were used for PCR amplification, and the amplification system was: 10 ⁇ PCR buffer.
  • PCR amplification conditions were: pre-denaturation at 95 ° C for 4 min, then denaturation at 95 ° C for 30 s, annealing at 57 ° C for 40 s, extension at 72 ° C for 1 min 30 s, 30 cycles.
  • the obtained 16S rDNA amplification product was subjected to electrophoresis detection, purification, and 3730 sequencing to obtain a 16S rDNA sequence of 1400 bp in length (see SEQ ID NO: 3 in the Sequence Listing). This sequence was subjected to blast alignment analysis in Genebank, and the result of identification of TM12-14 was Bifidobacterium pseudocatenulatum.
  • TM12-14 was white, convex, round, and the edges were neat, with colonies about 1-2 mm in diameter (Fig. 1). Observed under a microscope of 1000 times (Fig. 2), the cells showed a divergent rod shape, Gram staining was positive, and no spores and flagella were produced.
  • TM12-14 was negative for catalase reaction, negative for oxidase, and strictly anaerobic.
  • the carbon source utilization was tested using API 20A kit (Mérieux, France). The results are shown in Table 1 (+, indicating a positive reaction; -, indicating a negative reaction; w indicating a weak positive reaction).
  • the bioactive substance of TM12-14 mainly investigates the production of short chain fatty acids (SCFA) and organic acids in metabolites.
  • the TM12-14 was cultured for 48 hours, and 1 ml of the bacterial solution was centrifuged at 10,000 r/min for 5 minutes, and the supernatant was taken to prepare for detection of short-chain fatty acids (SCFA) and organic acids.
  • SCFA short-chain fatty acids
  • the detection of SCFA mainly detects the contents of four substances: acetic acid, propionic acid, butyric acid and valeric acid.
  • Agilent Meteorological Chromatograph GC-7890B, Agilent
  • HP-INNOWax Cross-Linked PEG
  • 30m ⁇ 0.25mm ⁇ 0.25um capillary column was used for analysis.
  • the detector was a hydrogen flame ion detector, and the GC parameter was set to Column temperature: 180 ⁇ 200°C; gasification chamber temperature: 240°C; detection temperature: 210°C; injection volume: 2 ⁇ L; carrier gas flow rate: N 2 , 50mL/min; hydrogen flow rate: 50mL/min; air flow rate: 600 ⁇ 700ml/min.
  • the selection criteria for organic acids are: 3-methylbutyric acid, valeric acid, quinic acid, lactic acid, oxalic acid, malonic acid, benzoic acid, maleic acid, succinic acid, anti-fumaric acid, malic acid, Diacid, tartaric acid, shikimic acid, citric acid, isocitric acid and L-ascorbic acid.
  • GC-7890B Agilent Meteorological Chromatograph
  • the column is selected from 122-5532G DB-5ms (40m ⁇ 0.25mm ⁇ 0.25um), column temperature: 270 ⁇ 290 ° C; inlet temperature: 250 ° C; gas Flow rate: 0.86 ml/min.
  • the drug-sensitive paper method was used for the experiment. 100 ul of the bacterial solution of the TM12-14 cultured in the log phase was plated, and the antibiotic susceptibility sheet was attached to the surface of the plate. The culture zone was cultured at 37 ° C for 48 hours, and the inhibition zone size was measured. The results are shown in Table 3.
  • TM12-14 was resistant to oxacillin, kanamycin and neomycin, and was sensitive to 17 other antibiotics.
  • Example 4 Tolerance of acid and bile salts of Bifidobacterium breve TM12-14
  • 0.3% bile salt medium was prepared, and 0.3% bile salt was added to PYG, and the cultured to log phase TM12-14 was inoculated to 0.3% PYG bile salt medium at a 10% inoculation amount, and cultured at 37 ° C. After 2 h, the same amount of normal PYG medium cultured TM12-14 bacterial solution and 0.3% PYG bile salt culture medium TM12-14 bacterial solution were plated and counted, and 0.3% of bile salts were calculated according to the following formula. Survival rate of treated TM12-14 bacteria:
  • TM12-14 has a certain tolerance to the conditions of pH 2.5 and 0.3% of bile salts, respectively.
  • Example 5 Cholesterol-lowering properties of Bifidobacterium breve TM12-14
  • the bile salt hydrolase was detected by TDCA method, and the TDAC plate was prepared.
  • 4% TDAC (sodium taurodeoxycholate) and 0.37 g/L CaCl 2 were added to the PYG solid medium, and TM12-14 was cultured to a concentration of about 10 8 cfu/ml, take 10ul of bacteria droplets on a 0.6mm diameter filter paper, place the filter paper on the surface of the TDAC plate, and incubate at 37 °C for 2 days to observe the white precipitate produced around the filter paper. The diameter of the white precipitate represents the gallbladder. Salt hydrolase activity.
  • the white precipitate of TM12-14 had a diameter of 8 mm, indicating that TM12-14 has bile salt hydrolase activity.
  • the method for determining the content of cholesterol is determined by the o-phthalaldehyde colorimetric method (OPA method), and the degradation ability of cholesterol is examined by the change of the cholesterol content of the strain in a certain concentration of cholesterol medium for a period of time.
  • OPA method o-phthalaldehyde colorimetric method
  • a certain amount of cholesterol was weighed and dissolved in ethanol at a concentration of 10 mg/mL, and sterilized by filtration. Add the prepared PYG medium to 10 mg/mL bile salt (autoclave), 10% mass concentration of sodium thioglycolate (filter sterilization) and cholesterol, mix well, and then wait for 3% of the inoculum. The test strain was inoculated into the medium. In addition to TM12-14, another commercially available cholesterol-lowering probiotic Lactobacillus plantarum Lp299v (purchased from Probi, Sweden) was used for comparison. Both bacteria were anaerobic at 37 °C. Incubate for 72 h under the conditions.
  • the culture solution containing the cholesterol-containing PYG medium was centrifuged at 10,000 r/min, and the supernatant was collected for cholesterol detection, and the uninoculated cholesterol PYG medium was used as a blank control group.
  • Take 1ml of the sample to be tested in a clean test tube add 6ml of 95% ethanol and 4ml of 50% KOH, shake and mix, then saponify in a 60 °C water bath for 10min, rapidly cool, add 10ml of n-hexane for extraction, fully Mix well, let stand for 20 min at room temperature, measure 8 ml organic phase (n-hexane layer) into another clean test tube, then dry it in nitrogen in a 60 ° C water bath, add 4 ml 0.5 g / L phthalaldehyde acetic acid solution, room temperature After standing for 10 min, 2 ml of concentrated H 2 SO 4 was added for 10 min, and finally, the absorbance at 550 nm was measured.
  • the cholesterol content in the medium before and after culture was calculated according to the standard curve.
  • the degradation rate of cholesterol was calculated according to the following formula:
  • L cholesterol degradation rate
  • A cholesterol content in the cholesterol medium not inoculated
  • B cholesterol content in the culture medium for 48 hours after the test strain is cultured.
  • TM12-14 had stronger cholesterol degradation ability than Lp299v.
  • Example 6 Treatment of UC mice by Bifidobacterium breve TM12-14
  • the treatment method was carried out by means of side-by-side administration, and the body weight, diet and drinking water of the mice were recorded every day, and the fecal traits and fecal occult blood of the mice were observed, on the first day, the third day, the fifth day and the first
  • the disease activity index (DAI) of the mice was calculated for 7 days, and the DAI scores are shown in Table 4.
  • the experiment lasted for 7 days, and the daily gavage volume of probiotics and PBS was 200 ul.
  • the mice were sacrificed. All mice were bled, necked, colonic, photographed, weighed, and the length of the colon was measured. Colon tissue was stored in a -80 ° C refrigerator and paraformaldehyde.
  • Stool characteristics in the table normal stool - forming stool; loose stool - paste-like, semi-formed stool that does not adhere to the anus; loose stool - a thin watery stool that can adhere to the anus.
  • blood in the stool normal mice have positive blood in the stool; the blood in the naked eye is red or brown; the occult blood is positive in the blood of the naked eye, and the test is performed using tetramethylbenzidine.
  • the DAI index is equal to the sum of the three points of weight, stool traits, and fecal occult blood/weak blood.
  • mice The body weight changes of mice before and after treatment are shown in Table 5 and Figure 4 below:
  • the colon tissue of the UC model mice changed, mainly because the ulcer tissue and inflammation caused the colon tissue to shorten. After the end of the treatment, the colon length of the mouse measured by anatomy is shown in Table 7.
  • Example 7 Food composition containing Bifidobacterium fuliginea TM12-14
  • Example 8 Pharmaceutical composition containing pseudo-small Bifidobacterium TM12-14
  • the raw material ratio is shown in Table 9.
  • lactose, yeast powder and peptone are mixed uniformly with purified water, preheated to 60-65 ° C, homogenized at 20 Mpa, sterilized at 90 ° C for 20-30 minutes, cooled to 36-38 ° C, mixed with protective agent vitamin C, Access to Bifidobacterium bifidum TM12-14 live bacteria (1-500 ⁇ 10 6 cfu/mL), ferment at pH 36-38 ° C to pH 6.0, centrifuge, freeze-dry to a moisture content of less than 3%, ie A pseudo-dried Bifidobacterium bifidum TM12-14 lyophilizate was prepared.
  • Bifidobacterium breve Bismuth TM12-14 lyophilizate 0.5 g was weighed in an equal amount with maltodextrin and then filled into capsules to prepare a pharmaceutical composition containing Bifidobacterium breve Bifidobacterium TM12-14.
  • Example 9 Preparation method of medicine for treating ulcerative enteritis (UC)
  • Preparation of pharmaceutical dosage form Add 5 volumes of growth factor and 1 volume of protective agent vitamin C to 100 volumes of TM12-14 fermented bacterial solution, mix well and mix, then add starch adjuvant (such as maltodextrin) to prepare the drug. Dosage form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供了一种假小链状双歧杆菌及其培养方法和应用，该假小链状双歧杆菌（Bifidobacterium pseudocatenulatum）TM12-14，保藏于广东省微生物菌种保藏中心，其保藏编号为GDMCC No：60089。该菌株能够显著改善溃疡性结肠炎小鼠的表现状态，降低小鼠疾病活动指数和炎症性反应，同时具有降低胆固醇的能力。

Description

一种假小链状双歧杆菌及其培养方法和应用 技术领域
本发明涉及微生物技术领域，尤其涉及一种假小链状双歧杆菌(Bifidobacterium pseudocatenulatum)及其培养方法和应用。
背景技术
人体肠道由大量的微生物组成，这些微生物种类繁多，数量庞大，在人肠道中形成一个复杂的生态系统，其中的微生物的组成与人体健康息息相关。大量研究表明，肠道微生物与很多疾病有着密切的关联，比如糖尿病、肥胖、高血脂等代谢性疾病和结肠炎、类风湿性关节炎等炎症性疾病。健康人体的肠道中有绝大多数的微生物属于有益菌，是人体健康不可缺少的种类，其中双歧杆菌是人肠道中一种重要的菌，双歧杆菌从出生开始在婴儿肠道中定殖，随着年龄的增长，双歧杆菌的含量逐渐下降。双歧杆菌具有抗炎、抗肿瘤、抗衰老以及抑制有害菌等重要功效，同时双歧杆菌也可以通过产生短链脂肪酸(SCFA)和有机酸刺激肠道蠕动，防止便秘等疾病。
溃疡性肠炎(Ulcerative colitis，UC)是炎症性肠病(Inflammatory bowel disease，IBD)的一种，是一种发病机制不明的慢性肠道炎症性疾病。临床病理研究认为UC的发病主要与个体易感基因以及肠道微生物引发的肠粘膜免疫反应有关，其症状主要表现为持续腹痛、腹泻和黏液血便，且病情反复，发病可见任何年龄阶段。
目前，临床上针对UC的用药主要有水杨酸类、糖皮质激素、免疫制剂。水杨酸类药物可以比较好地抑制前列腺素合成，清除氧自由基从而达到缓解炎症反应的目的，临床上治疗UC常见的水杨酸类西药主要是柳氮磺胺吡啶(SASP)，主要针对轻度、中度以及慢性UC患者；糖皮质激素是重症或者爆发性UC患者 的首选用药，比如倍他米松；免疫抑制剂如环孢素可以通过抑制T细胞IL-2的产生，影响免疫反应的进展，从而对UC进行抑制。
现有针对UC的三类药物均可以一定程度上对UC进行缓解，但是也都存在一定的副作用，水杨酸类的副作用是引发消化道反应、头痛、网织红细胞增多、精子减少及过敏反应引起的皮疹、肝毒性、白细胞减少、贫血等。糖皮质激素会导致机体代谢紊乱，水潴留等副作用，仅可作为应急用药，不能长期服用。免疫抑制剂治疗对药物依赖性较大，治疗周期长，容易引起肾毒性及二次感染，只能作为一种辅助治疗的手段。
发明内容
本发明提供一种假小链状双歧杆菌新种，具有预防和/或治疗溃疡性肠炎的作用。本发明进一步提供该肠道细菌新种的培养方法以及其制成的产品和其应用。
本发明包括如下技术方案：
根据本发明的第一方面，本发明提供一种假小链状双歧杆菌(Bifidobacterium pseudocatenulatum)TM12-14，其保藏于广东省微生物菌种保藏中心，其保藏编号为GDMCC 60089。
根据本发明的第二方面，本发明提供一种第一方面的假小链状双歧杆菌TM12-14的培养方法，将所述假小链状双歧杆菌TM12-14接种于PYG培养基中进行厌氧培养。
根据本发明的第三方面，本发明提供一种含有第一方面的假小链状双歧杆菌TM12-14和/或其代谢产物的微生态制剂。
按照本领域的通常理解，一切能促进正常微生物群生长繁殖及抑制致病菌生长繁殖的制剂都称为“微生态制剂”。本发明中，所称的“微生态制剂”，是指利用假小链状双歧杆菌TM12-14和/或其代谢产物制成的制剂，其具有调节肠道之 功效，快速构建肠道微生态平衡。典型的微生态制剂可以是益生菌制剂，用于预防/治疗溃疡性肠炎。作为本发明的益生菌，假小链状双歧杆菌TM12-14具有治疗溃疡性肠炎的效果，可通过进一步改变益生菌制剂类型，采用不同包装及加工方法，比如采用包埋技术保持菌种活性从而到达相应的治疗效果，或者通过额外添加益生元(菌粉、寡聚糖等)联用假小链状双歧杆菌TM12-14来治疗溃疡性肠炎都可实现同等的治疗效果。另外本发明的益生菌假小链状双歧杆菌TM12-14可以缓解溃疡性肠炎，还可能会在其他的一些炎症相关的疾病(普通肠炎、胃炎等)中发挥其治疗作用。
根据本发明的第四方面，本发明提供一种含有第一方面的假小链状双歧杆菌TM12-14和/或其代谢产物的食品组合物、保健品或辅料添加剂。
本发明中的食品组合物，除含有假小链状双歧杆菌TM12-14和/或其代谢产物以外，还可以含有各种食品原料或食品添加剂等，例如牛奶、白糖和维生素等。本发明中的辅料添加剂，例如各种食用性添加剂。
根据本发明的第五方面，本发明提供一种含有第一方面的假小链状双歧杆菌TM12-14和/或其代谢产物的药物组合物。
本发明中的药物组合物，除含有假小链状双歧杆菌TM12-14和/或其代谢产物以外，还可以含有各种药学上可接受的载体和/或辅料，包括但不限于：乳糖、酵母粉、蛋白胨、纯净水、淀粉和维生素等，还可以含有各种赋形剂，可以制成片剂或胶囊制剂等。此外，本发明中的药物组合物还可以含有有助于保持假小链状双歧杆菌TM12-14活力的物质，如保护剂，典型但非限定性的保护剂是维生素C。
本发明的药物组合物中，假小链状双歧杆菌TM12-14的含量可以按药物组合物的总体积或总重量计，例如，典型但非限定性地含有1×10-1至1×1020cfu/mL或cfu/g的假小链状双歧杆菌TM12-14，较佳地含有1×104至1×1015cfu/mL或cfu/g的假小链状双歧杆菌TM12-14。
根据本发明的第六方面，本发明提供第一方面的假小链状双歧杆菌TM12-14在制备预防和/或治疗溃疡性肠炎的药物中的应用。
根据本发明的第七方面，本发明提供第一方面的假小链状双歧杆菌TM12-14在制备微生态制剂中的应用。
根据本发明的第八方面，本发明提供第一方面的假小链状双歧杆菌TM12-14在制备食品组合物、保健品或辅料添加剂中的应用。
根据本发明的第九方面，本发明提供第一方面的假小链状双歧杆菌TM12-14在生产有机酸中的应用。
本发明中的有机酸，尤其是指短链脂肪酸(SCFA)，例如甲酸、乙酸、丁酸等，有机酸还可以包括3-甲基丁酸、戊酸、奎宁酸、乳酸、草酸、丙二酸、苯甲酸、马来酸、丁二酸、反富马酸、苹果酸、己二酸、酒石酸、莽草酸、柠檬酸、异柠檬酸和L-抗坏血酸中的一种或多种。
根据本发明的第十方面，本发明提供第一方面的假小链状双歧杆菌TM12-14在生产短链脂肪酸中的应用。
根据本发明的第十一方面，本发明提供一种预防和/或治疗溃疡性肠炎的方法，包括给受试对象施用第一方面的假小链状双歧杆菌TM12-14或第五方面的药物组合物。
根据本发明的第十二方面，本发明提供一种降低血脂、控制哺乳动物体重的下降、和/或降低哺乳动物的疾病活动指数(DAI)的方法，包括给受试对象施用第一方面的假小链状双歧杆菌TM12-14或第五方面的药物组合物。
本发明中，受试对象可以是人或其它哺乳动物。
经过研究发现，本发明的假小链状双歧杆菌TM12-14，对溃疡性肠炎有明显的缓解作用，具体表现在能够显著改善溃疡性结肠炎小鼠的表观状态，降低小鼠疾病活动指数，并降低小鼠炎症性反应，同时具有降胆固醇的能力。因此，该假小链状双歧杆菌TM12-14可以制成微生态制剂、食品组合物、药物组合物 等产品，用于溃疡性肠炎的预防和/或治疗之中。
保藏信息
菌株名称：Bifidobacterium pseudocatenulatum TM12-14
保藏日期：2016年10月13日
保藏单位：广东省微生物菌种保藏中心(GDMCC)
保藏地址：广东省广州市先烈中路100号大院59号楼5楼
保藏编号：GDMCC 60089
附图说明
图1显示了假小链状双歧杆菌TM12-14培养48h菌落的图片，菌落是白色、凸起、圆形、边缘整齐，菌落直径约1-2mm。
图2显示了假小链状双歧杆菌TM12-14在显微镜下的革兰氏染色图片(1000倍)，菌体呈现分歧杆状，革兰氏染色为阳性，没有芽孢和鞭毛产生。
图3显示了胆固醇标准曲线，采用邻苯二甲醛比色法(OPA法)进行胆固醇的检测，通过使用不同浓度(20ug/mL，40ug/mL，60ug/mL，80ug/mL)的胆固醇与OPA进行反应显色，得到标准曲线，线性回归的方程式为：y＝0.0085x+0.0072；相关系数R2为0.9992。
图4显示了对照组、模型组、VSL#3和TM12-14治疗组小鼠的体重的变化。
图5显示了对照组、模型组、VSL#3和TM12-14治疗组小鼠的DAI指数的变化。
具体实施方式
下面结合实施例对本发明做进一步的说明。
实施例1：假小链状双歧杆菌TM12-14的分离鉴定
1、样品收集
分离样品来自于一位14岁健康的男性粪便，将粪便采集至无菌的样品管中，1h内带回实验室进行分选。
2、双歧杆菌的分离纯化
收集的新鲜样品立刻转移至厌氧操作箱中，取0.2g样品于1ml无菌的PBS(磷酸缓冲液)中，充分震荡混匀，然后进行梯度稀释涂布，培养基采用PYG培养基(购自环凯微生物科技公司)，具体配方是(1L)：蛋白胨5g，胰化酪蛋白5g，酵母粉10g，牛肉膏5g，葡萄糖5g，K2HPO4 2g，Tween 80 1mL，Cysteine-HCl·H2O 0.5g，血红素5mg，维生素K11uL，无机盐溶液(每L无机盐溶液含有CaCl2·2H2O 0.25g，MgSO4·7H2O 0.5g，K2HPO4 1g，KH2PO4 1g，NaHCO310g，NaCl 2g)40mL，刃天青1mg，蒸馏水950mL，调节pH至6.8～7.0，115℃灭菌25min。固体培养基加入1.5％的琼脂，在厌氧操作箱中倾倒。涂布的平板置于37℃厌氧培养，厌氧的气体组分为N2：CO2：H2＝90：5：5。培养3天后，挑取单菌落进行划线分纯，获得每株单菌的纯培养。
3、菌种保藏
对获得的纯培养菌株进行培养，至浓度约为109cfu/ml，取400ul菌液添加40％甘油400ul，使其甘油浓度达到20％，然后进行-80℃超低温保藏。
4、16S rDNA鉴定
将获得的分离菌株在液体PYG培养基中培养24h，取1ml菌液进行10000r/min离心5min，收集菌体，提取基因组DNA。以基因组DNA作为模板，使用16S rDNA通用引物(8F-AGAGTTTGATCATGGCTCAG(SEQ ID NO：1)和1492R-TAGGGTTACCTTGTTACGACTT(SEQ ID NO：2))进行PCR扩增，扩增体系为：10×PCR缓冲液，3uL；dNTP，2.5uL；27F，0.5uL；1492R，0.5uL；Taq酶，0.3uL；模板，1uL；ddH2O，18.2uL。PCR扩增条件为：95℃预变性4min， 然后95℃变性30s，57℃退火40s，72℃延伸1min 30s，30个循环。将获得的16S rDNA扩增产物进行电泳检测、纯化、3730测序，获得长度为1400bp的16S rDNA序列(见序列表中SEQ ID NO：3)。将这段序列在Genebank中进行blast比对分析，获得TM12-14的鉴定结果为小链状双歧杆菌Bifidobacterium pseudocatenulatum。
5、TM12-14的生理生化特征
在PYG培养基上培养48小时，TM12-14的菌落是白色、凸起、圆形、边缘整齐，菌落直径约1-2mm(图1)。在1000倍的显微镜下观察(图2)，菌体呈现分歧杆状，革兰氏染色为阳性，没有芽孢和鞭毛产生。TM12-14的过氧化氢酶反应为阴性，氧化酶阴性，严格厌氧，碳源利用情况使用API 20A试剂盒(法国梅里埃)进行检测。结果如表1(+，表示阳性反应；-，表示阴性反应；w表示弱阳性反应)。
表1
Figure PCTCN2016111026-appb-000001
Figure PCTCN2016111026-appb-000002
实施例2：假小链状双歧杆菌TM12-14的生物活性物质
TM12-14的生物活性物质主要考察代谢产物中的短链脂肪酸(SCFA)和有机酸产生情况。
1、样品预处理
将TM12-14培养48h，取1ml菌液进行10000r/min离心5min，取上清，准备进行短链脂肪酸(SCFA)和有机酸的检测。
2、SCFA的测定
SCFA的检测主要检测乙酸、丙酸、丁酸、戊酸这4种物质的含量。采用安捷伦气象色谱仪(GC-7890B,Agilent)，选用HP-INNOWax(Cross-Linked PEG)，30m×0.25mm×0.25um的毛细柱进行分析，检测器为氢火焰离子检测器，GC参数设置为柱温：180～200℃；气化室温度：240℃；检测温度：210℃；进样量：2μL；载气流量：N2，50mL/min；氢气流量：50mL/min；空气流量：600～700ml/min。
3、有机酸的测定
有机酸的检测标准品选用：3-甲基丁酸，戊酸，奎宁酸，乳酸，草酸，丙二酸，苯甲酸，马来酸，丁二酸，反富马酸，苹果酸，己二酸，酒石酸，莽草酸，柠檬酸，异柠檬酸和L-抗坏血酸。仍然采用安捷伦气象色谱仪(GC-7890B,Agilent)，色谱柱选用122-5532G DB-5ms(40m×0.25mm×0.25um)，柱温：270～290℃；进样口温度：250℃；气体流量:0.86ml/min。
4、实验结果
结果如表2所示。
表2
Figure PCTCN2016111026-appb-000003
实施例3：假小链状双歧杆菌TM12-14的抗生素敏感情况
考察TM12-14对常见20种抗生素的敏感情况，采用药敏纸片法进行实验，取培养至对数期的TM12-14的菌液100ul进行平板涂布，将抗生素药敏片贴在平板表面，37℃培养48h，测量抑菌圈大小，其结果如表3。
表3
Figure PCTCN2016111026-appb-000004
Figure PCTCN2016111026-appb-000005
结果显示，TM12-14对苯唑西林、卡那霉素和新霉素有抗性，对其他17种抗生素比较敏感。
实施例4：假小链状双歧杆菌TM12-14对酸和胆盐的耐受能力
因人益生菌到达肠道需要经过胃和小肠，因此需要经历pH2.5左右的胃酸和0.3％浓度的胆盐。只有具有酸和胆盐耐受的菌才能到达肠道发挥益生作用。所以本实施例对TM12-14的酸和胆盐耐受情况作了考察。
1、TM12-14的酸耐受情况
配制pH 2.5的PYG培养基，将培养至对数期的TM12-14按照10％的接种量接种至pH2.5的PYG培养基中，37℃培养2h后取等量正常PYG培养基培养的TM12-14菌液和pH2.5的PYG培养基培养的TM12-14菌液进行平板涂布计 数，按下列公式计算pH2.5的条件下处理的TM12-14菌的存活率：
pH2.5处理存活率＝(pH2.5的PYG培养基培养的菌液平板涂布菌落个数/正常PYG培养基培养的菌液平板涂布菌落个数)×100％
结果显示TM12-14在pH2.5的条件下处理2h的存活率为78％。
2、TM12-14的胆盐耐受情况
配制0.3％的胆盐培养基，通过在PYG中添加0.3％的胆盐，将培养至对数期的TM12-14按照10％的接种量接种至0.3％的PYG胆盐培养基，37℃培养2h后取等量正常PYG培养基培养的TM12-14菌液和0.3％的PYG胆盐培养基培养的TM12-14菌液进行平板涂布计数，按下列公式计算0.3％的胆盐的条件下处理的TM12-14菌的存活率：
0.3％胆盐处理存活率＝(0.3％的PYG胆盐培养基培养的菌液平板涂布菌落个数/正常PYG培养基培养的菌液平板涂布菌落个数)×100％
结果显示TM12-14在0.3％的胆盐的条件下处理2h的存活率为65％。
通过以上耐受实验，TM12-14分别在pH2.5的条件和0.3％的胆盐的条件具有一定的耐受能力。
实施例5：假小链状双歧杆菌TM12-14的降胆固醇特性
1、TM12-14的胆盐水解酶活性
胆盐水解酶采用TDCA法进行检测，配制TDAC平板，PYG固体培养基中添加4％的TDAC(牛磺去氧胆酸钠)和0.37g/L的CaCl2，将TM12-14培养至浓度约108cfu/ml，取10ul菌液滴在直径为0.6mm的滤纸片上，滤纸片置于TDAC平板表面，37℃培养2天，观察滤纸片周边产生的白色沉淀情况，白色沉淀的直径代表胆盐水解酶的活性。
通过测量，TM12-14的白色沉淀的直径为8mm，表明TM12-14具有胆盐水解酶的活性。
2、TM12-14的体外降胆固醇情况
胆固醇的含量测定方法采用邻苯二甲醛比色法(OPA法)，通过菌株在含一定浓度的胆固醇培养基中培养一段时间的胆固醇含量前后的变化来考察对胆固醇的降解能力。具体方法如下：
(1)胆固醇培养基的配制和实验菌株的培养
称取一定质量的胆固醇溶解于乙醇中，浓度为10mg/mL，过滤除菌。将配置好的PYG培养基分别加入10mg/mL的胆盐(高压灭菌)，10％质量浓度的巯基乙酸钠(过滤除菌)和胆固醇，充分混匀，然后按照3％的接种量将待测菌株接种至该培养基中，待测菌株除了TM12-14，还选用另外一株商业降胆固醇益生菌植物乳杆菌Lp299v(购自瑞典Probi公司)作比较，两种菌都在37℃厌氧条件下培养72h。
(2)标准曲线的制作
精确量取0.5mg/mL的胆固醇标准溶液40uL，80uL，120uL，160uL，200uL于干净试管中，加入无水乙醇定容至1mL，每个试管中加入OPA4mL(0.5mg邻苯二甲醛加入到1mL冰醋酸)，震荡混匀，室温静置10min，然后加入2mL的浓硫酸混匀，静置反应10min，于550nm处测定吸光度。以浓度作为横坐标，吸光度作为纵坐标绘制标准曲线(图3)，通过计算，线性回归的方程式为：y＝0.0085x+0.0072；相关系数R2为0.9992。
(3)培养基中胆固醇的测定
将含有胆固醇的PYG培养基培养好的菌液进行10000r/min的离心，收集上清，进行胆固醇检测，同时以未接种的胆固醇PYG培养基作为空白对照组。取1ml待测样品于干净的试管中，加入95％乙醇6ml和50％的KOH 4ml，震荡混匀，然后在60℃水浴中进行皂化反应10min，迅速进行冷却，加入10ml正己烷进行萃取，充分混匀，室温静置20min，量取8ml有机相(正己烷层)到另一洁净试管中，然后在60℃水浴中进行氮气吹干，加入4ml 0.5g/L邻苯二甲醛乙酸 溶液，室温静置10min，添加2ml浓H2SO4反应10min，最后测量在550nm处的吸光值。
(4)胆固醇降解率的计算
根据标准曲线计算培养前后培养基中胆固醇的含量，胆固醇的降解率按以下公式进行计算：
L＝(A-B)/A×100％
L：胆固醇降解率；A：未接种菌的胆固醇培养基中胆固醇的含量；B：待测菌株培养48h培养液中胆固醇的含量。
(5)胆固醇降解结果
通过计算，得到TM12-14的胆固醇降解率为78％，而Lp299v降解率为70％，由此说明TM12-14比Lp299v具有更强的胆固醇降解能力。
实施例6：假小链状双歧杆菌TM12-14对UC小鼠的治疗
本实施例所选取的小鼠模型为：DSS诱导的溃疡性肠炎小鼠模型，采用C57bl/6小鼠(购自湖北医学实验动物中心)，8周龄，体重20g±2g，小鼠饲养环境为SPF级，适应性喂养1周进行DSS诱导，连续给小鼠饮用0.2％的DSS(葡聚糖硫酸钠，分子量36000-50000)7天。通过采用VSL#3(购自美国Sigma Tau)作为阳性对照，比较TM12-14和VSL#3的治疗效果。
试验小鼠总计48只，随机分为4组，每组12只，其中包括对照组(control组)，DSS诱导的模型组(每只每天灌胃0.2ml PBS)，TM12-14治疗组和VSL#3治疗组。TM12-14处理过程为：培养24h的TM12-14菌液，离心收集菌体，用PBS进行悬浮，调整菌浓度至109cfu/ml，每只小鼠每天灌胃200ul的TM12-14。VSL#3也采用PBS进行悬浮，同样调节浓度至109cfu/ml，每只小鼠每天灌胃200ul。治疗方法采用边造模边给药的方式，每天记录小鼠体重、饮食和饮水情况，同时观察小鼠的粪便性状及粪便隐血情况，分别在第1天、第3天、第5天和第7天计算小鼠的疾病活动指数(DAI)，DAI评分详见表4。实验持续7 天，益生菌和PBS的日灌胃量为200ul。实验结束后处死小鼠，所有小鼠取血、脱颈、取结肠、拍照、称重、量取结肠长度。结肠组织保存于-80℃冰箱和多聚甲醛中。
表4.DAI指数评分表
Figure PCTCN2016111026-appb-000006
表中的大便性状：正常大便—成形大便；松散大便—不粘附于肛门的糊状、半成型大便；稀便—可粘附于肛门的稀样水便。其中便血情况：正常小鼠便血为阳性；肉眼血便为红色或褐色；隐血阳性为不明显的肉眼血便，使用四甲基联苯胺进行检测。DAI指数等于体重、大便性状以及大便隐血/弱眼血便三个积分之和。
治疗前后小鼠的体重变化如下表5和图4所示：
表5
Figure PCTCN2016111026-appb-000007
Figure PCTCN2016111026-appb-000008
从表5和图4中的结果可以得知，对照组小鼠的体重基本维持缓慢升高的趋势，DSS诱导的模型组下属的体重逐渐下降，第3天开始体重下降的比较显著(*P<0.05)，第5天开始，二者之间的差异显著程度更加明显(**P<0.01)。而TM12-14和VSL#3的治疗可以减缓UC小鼠体重的下降，在第7天，TM12-14和VSL#3小鼠的体重下降的控制相对于模型组比较显著(▲P<0.05)。说明这两组益生菌可以控制UC引起的体重下降情况。通过比较第7天各组的体重数值可以发现TM12-14组小鼠的体重略高于VSL#3，说明TM12-14在控制UC小鼠体重降低的能力好于VSL#3。
DSS诱导的溃疡性肠炎的小鼠由于体重下降、大便性状和便血情况的变化引起DAI指数的变化，小鼠DAI指数在治疗前后的变化如表6和图5：
表6
Figure PCTCN2016111026-appb-000009
表6和图5数据表明，对照组小鼠的DAI维持一个正恒定的低水平，而DSS诱导的小鼠由于出现一系列病理，导致DAI逐渐升高，第3天开始模型组小鼠DAI相对对照组变得极显著(**P<0.01)，第7天模型组小鼠DAI达到最高水平。益生菌的干预可以控制DAI的升高，TM12-14和VSL#3组小鼠在第7天的DAI相对于模型组得到了一定程度的控制(▲P<0.05)。通过第7天的DAI数值可以 发现TM2-14组小鼠的DAI略低于VSL#3，可以说明TM12-14在控制UC小鼠DAI升高的效果优于VSL#3。
UC模型小鼠的结肠组织会发生改变，主要是因为溃疡和炎症的发生导致结肠组织缩短，治疗结束后，通过解剖测量的小鼠结肠长度见表7。
表7
Figure PCTCN2016111026-appb-000010
表7结果显示，在进行DSS诱导7天后的小鼠(模型组)的结肠组织缩短情况比较严重，与对照组相比较差异极显著(**P<0.01)。而益生菌TM12-14和VSL#3的干预可以显著控制小鼠结肠的缩短(相对于模型组▲P<0.05)。通过表中数据可以发现TM12-14组小鼠的结肠长度比VSL#3组小鼠结肠长度长，可以说明TM12-14在控制UC小鼠结肠缩短的能力强于VSL#3。
实施例7：含假小链状双歧杆菌TM12-14的食品组合物
原料配比如表8。
表8
原料 质量百分比(％)
假小链状双歧杆菌TM12-14 0.5
牛奶 90.0
白糖 9.0
维生素C 0.5
按照上述配方比例混合牛奶、白糖，搅拌至完全混合，预热，20Mpa压力均质，90℃左右杀菌5-10分钟，冷却至40-43℃，混入保护剂维生素C，接种1-100×106cfu/g的假小链状双歧杆菌TM12-14菌，即制成含假小链状双歧杆菌TM12-14菌的食品组合物。
实施例8：含假小链状双歧杆菌TM12-14的药物组合物
原料配比见表9。
表9
原料 质量百分比(％)
假小链状双歧杆菌TM12-14 1.0
乳糖 2.0
酵母粉 2.0
蛋白胨 1.0
纯净水 93.5
维生素C 0.5
按照比例将乳糖、酵母粉、蛋白胨以纯净水混合均匀，预热到60-65℃，20Mpa压力均质，90℃左右杀菌20-30分钟，冷却至36-38℃，混入保护剂维生素C，接入假小链状双歧杆菌TM12-14活菌(1-500×106cfu/mL)，36-38℃发酵至pH值为6.0，离心，冷冻干燥至水份含量小于3％，即制备假小链状双歧杆菌TM12-14菌冷冻干燥物。称取0.5克假小链状双歧杆菌TM12-14冷冻干燥物与麦芽糊精等量混合后装入胶囊中，即制成含假小链状双歧杆菌TM12-14菌的药物组合物。
实施例9：用于治疗溃疡性肠炎(UC)的药物的制备方法
1、菌液准备：将假小链状双歧杆菌TM12-14(1×109cfu/ml)进行厌氧培养，厌氧培养基采用PYG培养基，经过37℃厌氧发酵2-3天。
2、生长因子制备：将脱脂牛奶、酪蛋白进行混合、离心、超滤获得牛奶生长因子粗提物(含有维生素类物质、嘌呤类物质、嘧啶类物质等成分)。
3、药物剂型制作：将5体积生长因子和1体积的保护剂维生素C加入到100体积的TM12-14发酵的菌液中，充分搅拌混匀，然后加入淀粉辅料(如麦芽糊精)制备药物剂型。
以上内容是结合具体的实施方式对本发明所作的进一步详细说明，不能认定本发明的具体实施只局限于这些说明。对于本发明所属技术领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干简单推演或替换，都应当视为属于本发明的保护范围。

Claims (15)

  1. 一种假小链状双歧杆菌(Bifidobacterium pseudocatenulatum)TM12-14，其保藏于广东省微生物菌种保藏中心，其保藏编号为GDMCC 60089。
  2. 一种权利要求1所述的假小链状双歧杆菌TM12-14的培养方法，其特征在于，将所述假小链状双歧杆菌TM12-14接种于PYG培养基中进行厌氧培养。
  3. 一种含有权利要求1所述的假小链状双歧杆菌TM12-14和/或其代谢产物的微生态制剂。
  4. 一种含有权利要求1所述的假小链状双歧杆菌TM12-14和/或其代谢产物的食品组合物、保健品或辅料添加剂。
  5. 一种含有权利要求1所述的假小链状双歧杆菌TM12-14和/或其代谢产物的药物组合物。
  6. 如权利要求5所述的药物组合物，其特征在于，按所述药物组合物的总体积或总重量计，所述药物组合物含有1×10-1至1×1020cfu/mL或cfu/g的假小链状双歧杆菌TM12-14，较佳地含有1×104至1×1015cfu/mL或cfu/g的假小链状双歧杆菌TM12-14。
  7. 如权利要求在5所述的药物组合物，其特征在于，所述药物组合物还含有药学上可接受的载体和/或辅料。
  8. 如权利要求在5所述的药物组合物，其特征在于，所述药物组合物还含有有助于保持假小链状双歧杆菌TM12-14活力的物质。
  9. 权利要求1所述的假小链状双歧杆菌TM12-14在制备预防和/或治疗溃疡性肠炎的药物中的应用。
  10. 权利要求1所述的假小链状双歧杆菌TM12-14在制备微生态制剂中的应用。
  11. 权利要求1所述的假小链状双歧杆菌TM12-14在制备食品组合物、保健品或辅料添加剂中的应用。
  12. 权利要求1所述的假小链状双歧杆菌TM12-14在生产有机酸中的应用。
  13. 权利要求1所述的假小链状双歧杆菌TM12-14在生产短链脂肪酸中的应用。
  14. 一种预防和/或治疗溃疡性肠炎的方法，其特征在于，给受试对象施用权利要求1所述的假小链状双歧杆菌TM12-14或权利要求5所述的药物组合物。
  15. 一种降低血脂、控制哺乳动物体重的下降、和/或降低哺乳动物的疾病活动指数的方法，其特征在于，给受试对象施用权利要求1所述的假小链状双歧杆菌TM12-14或权利要求5所述的药物组合物。
PCT/CN2016/111026 2016-12-20 2016-12-20 一种假小链状双歧杆菌及其培养方法和应用 WO2018112739A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/111026 WO2018112739A1 (zh) 2016-12-20 2016-12-20 一种假小链状双歧杆菌及其培养方法和应用
CN201680091077.1A CN110023484B (zh) 2016-12-20 2016-12-20 一种假小链状双歧杆菌及其培养方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/111026 WO2018112739A1 (zh) 2016-12-20 2016-12-20 一种假小链状双歧杆菌及其培养方法和应用

Publications (1)

Publication Number Publication Date
WO2018112739A1 true WO2018112739A1 (zh) 2018-06-28

Family

ID=62624451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/111026 WO2018112739A1 (zh) 2016-12-20 2016-12-20 一种假小链状双歧杆菌及其培养方法和应用

Country Status (2)

Country Link
CN (1) CN110023484B (zh)
WO (1) WO2018112739A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113897302A (zh) * 2021-08-06 2022-01-07 东北农业大学 一种可缓解结肠炎的双歧杆菌及其应用
CN113943682A (zh) * 2020-11-12 2022-01-18 江南大学 缓解便秘的长双歧杆菌长亚种及其制备的发酵食品与益生菌制剂
WO2023118868A1 (en) * 2021-12-21 2023-06-29 Quadram Institute Bioscience Bifidobacterium and compositions thereof for breast cancer treatment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110331119B (zh) * 2019-08-19 2022-04-29 江南大学 两歧双歧杆菌ccfm1063及其应用
CN115478031A (zh) * 2022-09-28 2022-12-16 中国科学院深圳先进技术研究院 防治炎症性肠病的胆汁酸代谢菌及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013558A8 (en) * 2001-07-30 2003-08-14 Simone Claudio De Treatment of radiation-induced diarrhea with probiotics
CN103619343A (zh) * 2010-12-07 2014-03-05 高等科学研究委员会 双歧杆菌cect7765及其在预防和/或治疗超重、肥胖和相关病理中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013558A8 (en) * 2001-07-30 2003-08-14 Simone Claudio De Treatment of radiation-induced diarrhea with probiotics
CN103619343A (zh) * 2010-12-07 2014-03-05 高等科学研究委员会 双歧杆菌cect7765及其在预防和/或治疗超重、肥胖和相关病理中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORDONI, ALESSANDRA: "Cholesterol-lowering probiotics:in vitro selection and in vivo testing of bifidobacteria", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 97, no. 18, 30 September 2013 (2013-09-30), pages 8273 - 8281, XP035329698, ISSN: 0175-7598 *
HARRINGTON, CARL R.: "A short-oligonucleotide microarray that allows imp- roved detection of gastrointestinal tract microbial communities", BMC MICROBIOLOGY, vol. 8, no. 1, 11 November 2008 (2008-11-11), pages 1 - 20, XP021048142, ISSN: 1471-2180 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113943682A (zh) * 2020-11-12 2022-01-18 江南大学 缓解便秘的长双歧杆菌长亚种及其制备的发酵食品与益生菌制剂
CN113897302A (zh) * 2021-08-06 2022-01-07 东北农业大学 一种可缓解结肠炎的双歧杆菌及其应用
CN113897302B (zh) * 2021-08-06 2022-08-09 东北农业大学 一种可缓解结肠炎的双歧杆菌及其应用
WO2023118868A1 (en) * 2021-12-21 2023-06-29 Quadram Institute Bioscience Bifidobacterium and compositions thereof for breast cancer treatment

Also Published As

Publication number Publication date
CN110023484A (zh) 2019-07-16
CN110023484B (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
WO2018112739A1 (zh) 一种假小链状双歧杆菌及其培养方法和应用
CN111280252B (zh) 长双歧杆菌长亚种、含其的组合物及用途
WO2018112741A1 (zh) 一种嗜酸乳杆菌及其培养方法和应用
CN113122466B (zh) 粪肠球菌及其应用
CN113755409B (zh) 一种缓解胰岛素抵抗的长双歧杆菌及其应用
WO2021143621A1 (zh) Anaerostipes sp B2131菌及其在炎症性肠病中的应用
WO2018112740A1 (zh) 一种加氏乳杆菌及其培养方法和应用
CN116083325B (zh) 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用
CN114774315B (zh) 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途
WO2019227418A1 (zh) 一种组合物及其应用
JP6990303B2 (ja) Ｍｅｇａｍｏｎａｓ ｆｕｎｉｆｏｒｍｉｓ及びその適用
JP2018532380A (ja) 腸内細菌の酪酸桿菌（Ｂｕｔｙｒｉｂａｃｔｅｒ ｉｎｔｅｓｔｉｎｉ）およびその使用
CN113797232B (zh) 具有缓解胰岛素抵抗功能的组合物及其应用
JP4540664B2 (ja) グルタミン産生能を有する新規のＢｉｆｉｄｏｂａｃｔｅｒｉｕｍ菌株
CN117106672B (zh) 一种改善衰老相关的认知障碍的短双歧杆菌及其应用
CN116814510B (zh) 一株能够预防或改善阿尔茨海默症的鼠李糖乳杆菌opb41和应用
WO2019227414A1 (zh) 一种组合物及其应用
WO2018027898A1 (zh) 一种产丁酸栖粪杆菌及其培养方法和应用
WO2019227417A1 (zh) 一种组合物及其应用
WO2018107364A1 (zh) 深圳柯林斯菌(Collinsella shenzhenensis)及其应用
CN110062806B (zh) 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
CN117286078B (zh) 一种改善胃肠道健康的植物乳植杆菌及其应用
CN112218646B (zh) 一种组合物及其应用
CN114990004B (zh) 一种分泌型免疫球蛋白a包裹态罗伊氏乳杆菌及防治妊娠糖尿病的应用
CN117917475A (zh) 一种调节肠道菌群的植物乳植杆菌p16及其应用、产品和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16924229

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16924229

Country of ref document: EP

Kind code of ref document: A1